Advertisement

Digestive Diseases and Sciences

, Volume 59, Issue 9, pp 2294–2298 | Cite as

Increased Rates of Duodenal Obstruction in Pancreatic Cancer Patients Receiving Modern Medical Management

  • Ashish Shah
  • Abbas Fehmi
  • Thomas J. Savides
Original Article

Abstract

Background

Duodenal obstruction from pancreatic cancer historically occurs in 2–25 % of patients without surgery, but with new advances in chemotherapy and radiation therapy, the life expectancy of pancreatic cancer has increased.

Aim

The aim of the study was to determine the rate of development of duodenal obstruction requiring intervention in patients with pancreatic head adenocarcinoma who do not undergo surgical resection, but receive modern chemoradiation.

Methods

It is a retrospective single center study. Inclusion criteria were patients with pancreatic cancer who underwent ERCP with metal biliary stent and then chemoradiation who subsequently developed symptomatic duodenal obstruction and underwent either metal duodenal stent placement or surgical duodenal bypass.

Results

Twenty-four of 63 patients (38 %, 95 % CI 26–50 %) with unresectable pancreatic cancer and biliary stents who received chemotherapy and/or radiation therapy developed duodenal obstruction. The average length of time from diagnosis of pancreatic adenocarcinoma to development of outlet obstruction was 11.4 ± 4.9 months (range 1.5–40 months). Average length of time from development of duodenal obstruction to death was 4.8 ± 2.1 months (range 0.5–60 months). Average survival time from diagnosis to death was 16.6 ± 5.6 months (range 4.5–58 months).

Conclusion

Thirty-eight percent of patients with unresectable pancreatic head adenocarcinoma and metal biliary stents who receive chemotherapy and/or radiation therapy eventually develop symptomatic duodenal obstruction requiring duodenal stent or surgical bypass. This rate of duodenal obstruction is nearly twice that of previous reports using older oncologic therapy and will likely increase as patients survive longer with advances in medical therapy for pancreatic cancer.

Keywords

Pancreatic cancer Duodenal obstruction Duodenal stent Enteric stent Pancreatic adenocarcinoma 

Notes

Conflict of interest

None.

References

  1. 1.
    Warshaw AL, Swanson RS. Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg. 1988;208:541–553.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery. 1982;91:123–133.PubMedGoogle Scholar
  3. 3.
    Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg. 1992;79:8–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 1990;212:132–139.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Egrari S, O’Connell TX. Role of prophylactic gastroenterostomy for unresectable pancreatic carcinoma. Am Surg. 1995;61:862–864.PubMedGoogle Scholar
  6. 6.
    Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg. 1999;188:649,55; discussion 655–657.Google Scholar
  7. 7.
    Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230:322,8; discussion 328–330.Google Scholar
  8. 8.
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.PubMedGoogle Scholar
  9. 9.
    Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012;43:205–217.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Loehrer PJS, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2011;29:4105–4112.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.PubMedCrossRefGoogle Scholar
  12. 12.
    Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801–808.PubMedCrossRefGoogle Scholar
  13. 13.
    Jeurnink SM, Steyerberg EW, Hof G, van Eijck CH, Kuipers EJ, Siersema PD. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. J Surg Oncol. 2007;96:389–396.PubMedCrossRefGoogle Scholar
  14. 14.
    Jeurnink SM, Steyerberg EW, van Hooft JE, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71:490–499.PubMedCrossRefGoogle Scholar
  15. 15.
    Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Adler DG, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol. 2002;97:72–78.PubMedCrossRefGoogle Scholar
  17. 17.
    van Hooft JE, Uitdehaag MJ, Bruno MJ, et al. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69:1059–1066.PubMedCrossRefGoogle Scholar
  18. 18.
    Mehta S, Hindmarsh A, Cheong E, et al. Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. Surg Endosc. 2006;20:239–242.PubMedCrossRefGoogle Scholar
  19. 19.
    Maire F, Hammel P, Ponsot P, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol. 2006;101:735–742.PubMedCrossRefGoogle Scholar
  20. 20.
    Doberneck RC, Berndt GA. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg. 1987;122:827–829.PubMedCrossRefGoogle Scholar
  21. 21.
    Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 1991;9:1682.PubMedGoogle Scholar
  22. 22.
    DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991;9:2128.PubMedGoogle Scholar
  23. 23.
    Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–331.PubMedCrossRefGoogle Scholar
  24. 24.
    Cho YK, Kim SW, Hur WH, et al. Clinical outcomes of self-expandable metal stent and prognostic factors for stent patency in gastric outlet obstruction caused by gastric cancer. Dig Dis Sci. 2010;55:668–674.PubMedCrossRefGoogle Scholar
  25. 25.
    Hamada T, Nakai Y, Isayama H, et al. Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate. Surg Endosc. 2013;27:1243–1248.PubMedCrossRefGoogle Scholar
  26. 26.
    Moura EG, Ferreira FC, Cheng S, Moura DT, Sakai P, Zilberstain B. Duodenal stenting for malignant gastric outlet obstruction: prospective study. World J Gastroenterol. 2012;18:938–943.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    van den Berg MW, Haijtink S, Fockens P, et al. First data on the evolution duodenal stent for palliation of malignant gastric outlet obstruction (DUOLUTION study): a prospective multicenter study. Endoscopy. 2013;45:174–181.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineUniversity of California San DiegoLa JollaUSA

Personalised recommendations